Results 111 to 120 of about 29,702 (243)

Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial

International Journal of Women's Health, 2013
Josep Lluis Carbonell Esteve,1 Rita Acosta,2 Yasmirian Pérez,2 Barbara Rodriguez,2 Isabel Seigler,2 Carlos Sanchez,2 Giuseppe Tomasi3 1Mediterránea Médica Clinic, Valencia, Spain; 2Eusebio Hernández Gynecology and Obstetrics ...
Esteve Carbonell JL, Acosta R, Perez Y, Rodriguez B, Seigler I, Sanchez C, Tomasi G   +6 more
doaj  

Educating Midwives as Abortion Providers: Implementing Innovative Models for Standardized Training in Abortion Care

Journal of Midwifery &Women's Health, Volume 71, Issue 2, Page 255-263, March/April 2026.
Abstract The Dobbs v Jackson Women's Health Organization US Supreme Court decision significantly limited patients' access to abortion services, and the providers who can legally deliver this care. Currently 22 states license providers other than physicians to provide medication or procedural abortion.
Nicole Quinones, Samantha Auerbach, Nikki Lanshaw, Nikia Grayson, Julie Blumenfeld, Becca Neuwirth, Pamela Pearson, Ellen Chaney Solis, Robyn Nisi, Kylea L. Liese   +9 more
wiley   +1 more source

Management of early pregnancy loss with mifepristone and misoprostol: clinical predictors of success from a randomized trial.

American Journal of Obstetrics and Gynecology, 2019
BACKGROUND Early pregnancy loss (EPL) is a common event in the first trimester, occurring in 15-20% of recognized pregnancies. A common evidence-based medical regimen for EPL management uses the prostaglandin E1 analogue misoprostol 800 mcg self ...
S. Sonalkar, N. Koelper, M. Creinin, J. Atrio, M. Sammel, A. McAllister, C. Schreiber   +6 more
semanticscholar   +1 more source

“Just Stay Home and Wait It Out”: Exploring Challenges Accessing Care for Miscarriage in Indiana

Perspectives on Sexual and Reproductive Health, Volume 58, Issue 1, Page 69-76, March 2026.
ABSTRACT Introduction Qualitative research on miscarriage in the United States primarily draws on the experiences of participants recruited from healthcare settings which may fail to robustly illuminate how people navigate to care. We aimed to explore the miscarriage experiences of Indiana residents, identify barriers to access, and generate ...
Kathryn J. LaRoche, Anayra Maldonado Quiles, Oluwapamimo J. Fafowora, Fatimah Lawal   +3 more
wiley   +1 more source

Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1:physiological regulator and pharmacological target for energy partitioning [PDF]

, 2007
The major glucocorticoid in man, cortisol, plays important roles in regulating fuel metabolism, energy partitioning and body fat distribution.
Alberts, Andrew, Brian R. Walker, Garrel, Havel, Lottenberg, Nowak, Pasquali, Paulmyer-Lacroix, Phillipou, Rask, Rosmond, Sapolsky, Stewart, Walker   +14 more
core   +1 more source

Could implementation of mifepristone address Canada’s urban–rural abortion access disparity: a mixed-methods implementation study protocol

BMJ Open, 2019
Introduction In January 2017, mifepristone-induced medical abortion was made available in Canada. In this study, we will seek to (1) understand facilitators and barriers to the implementation of mifepristone across Canada, (2) assess the impact of a ...
W. Norman, S. Munro, Melissa Brooks, Courtney Devane, E. Guilbert, R. Renner, T. Kendall, J. Soon, A. Waddington, M. Wagner, S. Dunn   +10 more
semanticscholar   +1 more source

Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial.

Obstetrics and Gynecology, 2019
OBJECTIVE To estimate the efficacy and safety of mifepristone antagonization with high-dose oral progesterone. METHODS We planned to enroll 40 patients in a double-blind, placebo-controlled, randomized trial.
M. Creinin, M. Hou, Laura Dalton, R. Steward, Melissa J. Chen   +4 more
semanticscholar   +1 more source

Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor

Anticancer Research, 2019
Case Report: Case 1 of an investigator-initiated study using oral single agent mifepristone to halt stage IV non-small cell lung cancer whose tumor was devoid of any targeted markers has remained ECOG zero and in good health for over 3 years.
J. Check, D. Check, T. Poretta
semanticscholar   +1 more source

Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH)

Journal of Clinical Endocrinology and Metabolism, 2019
Context Primary bilateral macronodular adrenal hyperplasia (BMAH) is a rare form of adrenal Cushing syndrome conventionally treated with adrenalectomy. Medical treatment is often reserved for patients not eligible for surgery. However, to date there have
P. Cohan, H. East, Sandi-Jo Galati, Jennifer U. Mercado, Precious J. Lim, Michele Lamerson, James J. Smith, A. Peters, K. Yuen   +8 more
semanticscholar   +1 more source

Use of recombinant virus replicon particles for vaccination against Mycobacterium ulcerans disease [PDF]

, 2015
Buruli ulcer, caused by infection with Mycobacterium ulcerans, is a necrotizing disease of the skin and subcutaneous tissue, which is most prevalent in rural regions of West African countries.
Bolz, Miriam, Kerber, Sarah, Pluschke, Gerd, Zimmer, Gert   +3 more
core   +3 more sources